Samuel Kim, MD

Highlights

1
American journal of preventive cardiology · 2023
LKLuke Kim JWJim W. Cheung DNDmitriy N. Feldman PGParag Goyal+2 more →SKSamuel Kim
PMID: 36923367PMCID: PMC10009437DOISenior author15 citations

Publications

Funding

Active

1 grant

Sub-PI
Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
National Heart, Lung, and Blood Institute · 2026–2031 · via Duke University
UG3HL181434-01

Clinical research

Active

5 studies

PI
Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
PHASE3 · Duke University · OPEN TO ACCRUAL (as of 2026)
Coronary Artery Disease Risk Factors Multiple; Coronary Artery Disease Progression; Prevention & Control; Premature Atherosclerosis
NCT07232069
PI
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event
PHASE3 · Eli Lilly and Company · OPEN TO ACCRUAL (as of 2026)
Elevated Lp(a); Atherosclerotic Cardiovascular Disease (ASCVD)
NCT07157774
PI
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia
PHASE2 · Eli Lilly and Company · OPEN TO ACCRUAL (as of 2026)
Severe Hypertriglyceridemia
NCT07269210
PI
A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.
PHASE3 · Novartis Pharma AG · OPEN TO ACCRUAL (as of 2025)
Hyperlipoproteinemia (a)
NCT05900141
PI
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
PHASE2 · Novartis Pharma AG · OPEN TO ACCRUAL (as of 2024)
Aortic Stenosis
NCT05646381

Completed & closed trials (8)

PI
A Treatment Protocol for the Use of Plozasiran in Adults With Familial Chylomicronemia Syndrome (FCS). A Single Patient Protocol for the Use of Plozasiran In Adolescents With Familial Chylomicronemia Syndrome (FCS). An Expanded Access Treatment Protocol for Use of Plozasiran In Adults With High-Risk Severe Hypertriglyceridemia (SHTG).
Arrowhead Pharmaceuticals INC · IRB STUDY CLOSURE (as of 2026)
Familial Chylomicronemia; High Risk Severe Hypertriglyceridemia (SHTG)
NCT06796426
PI
Prevalence of Systemic Inflammation in Patients With Atherosclerotic Cardiovascular Disease and Heart Failure
Novo Nordisk Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2025)
Cardiovascular Risk; Heart Failure; Chronic Kidney Disease
NCT06122961
PI
Measurement and Distribution of Lp(a) in Patients with High Risk Vascular Disease - Lp(a) Registry
Silence Therapeutics plc · IRB STUDY CLOSURE (as of 2025)
PI
A simple audit of cardiovascular risk factor management: SUrvey of Risk Factors in Coronary Heart Disease (SURF CHD) II
University Medical Center Utrecht · IRB STUDY CLOSURE (as of 2024)
PI
EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
PHASE4 · Amgen, Inc. · CLOSED TO ACCRUAL (as of 2024)
Cardiovascular Disease; Myocardial Infarction; Stroke; Coronary Revascularization
NCT05284747
PI
A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an "Inclisiran First" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (≥70 mg/dL) Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
PHASE3 · Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2024)
Atherosclerotic Cardiovascular Disease
NCT04929249
PI
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
PHASE3 · Novartis Pharmaceuticals Corporation · CLOSED TO ACCRUAL (as of 2023)
Atherosclerotic Cardiovascular Disease
NCT05030428
PI
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
PHASE3 · Novartis Pharmaceuticals Corporation · CLOSED TO ACCRUAL (as of 2022)
Cardiovascular Disease and Lipoprotein(a)
NCT04023552